[Expert consensus on safety management of bone-modifying agents]
- PMID: 34289552
- DOI: 10.3760/cma.j.cn112152-20210413-00312
[Expert consensus on safety management of bone-modifying agents]
Abstract
Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs.
骨改良药物目前包括双膦酸盐和地舒单抗，是治疗恶性肿瘤骨转移、高钙血症和骨质疏松的主要药物。由于骨改良药物广泛应用，其药物的不良反应逐渐增多，影响患者的生活质量。中国医师协会肿瘤医师分会乳腺癌学组和中国抗癌协会国际医疗交流分会组织相关专家，基于循证医学证据，深入探讨骨改良药物不良反应的管理，并提出合理建议，以指导临床医师提高对骨改良药物的安全性管理。.
Keywords: Adverse event; Bone metastasis; Bone-modifying agent; Expert consensus; Malignant tumor.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
